# Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening

> **NCT05043077** · PHASE4 · COMPLETED · sponsor: **Aristotle University Of Thessaloniki** · enrollment: 83 (actual)

## Conditions studied

- Retinopathy of Prematurity

## Interventions

- **DRUG:** Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%
- **DRUG:** Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%

## Key facts

- **NCT ID:** NCT05043077
- **Lead sponsor:** Aristotle University Of Thessaloniki
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-07
- **Primary completion:** 2023-01-20
- **Final completion:** 2023-01-23
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2025-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043077, "Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05043077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*